Design Highlights
- Medicare currently excludes GLP-1 receptor agonists for obesity, allowing coverage only for diabetes and cardiovascular issues.
- A proposed rule by CMS seeks to reinterpret this exclusion, potentially expanding access to AOMs for obesity treatment.
- The 2026 Part D Final Rule rejected AOM coverage for obesity due to estimated costs of $35 billion from 2026 to 2034.
- Medicaid coverage for GLP-1s for obesity varies by state, with only 13 states currently offering it.
- State-level differences in Medicaid policy contribute to unequal access to obesity medications across the country.
In the tangled web of healthcare, GLP-1 drugs are a hot topic, especially when it comes to obesity coverage. They’re marketed as miracle workers for weight loss, but don’t hold your breath. Medicare’s rules are as clear as mud. The current statute? It outright bans coverage of drugs meant for weight loss. Yup, that’s right. GLP-1 receptor agonists and other anti-obesity medications (AOMs) are excluded from Medicare Part D if they’re prescribed just for obesity. So, if you’re hoping for a little help with those extra pounds, good luck.
But wait, there might be a glimmer of hope. The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule. This would “reinterpret” the exclusion, paving the way for Part D to cover AOMs when used for obesity. Not just weight loss. Think of it as an attempt to redefine a problem. If approved, this would mean Medicare could finally cover these medications for reducing excess body weight. But let’s not get too excited. The rule change is still on the table, and who knows if it will ever see the light of day.
Now, let’s talk about the 2026 Medicare Part D Final Rule. Released under the Trump Administration, it didn’t embrace the idea of covering GLP-1 drugs for obesity. Sure, they’re fine for diabetes or cardiovascular issues, but obesity? Nope. The math is straightforward: covering GLP-1s for obesity could cost Medicare a whopping $35 billion from 2026 to 2034. That’s a big pill to swallow, and the Administration just said, “Not appropriate at this time.” Thanks for the clarity. Meanwhile, Medicare beneficiaries classified as obese represent a significant portion of those who could benefit from such coverage.
On the flip side, Medicare does cover some obesity treatments. Intensive behavioral therapy? Yes, if you have a BMI over 30. Bariatric surgery? Sure, if your BMI is over 35 and you have other related health issues. ICD-10 acknowledges obesity as a chronic disease, but commercial weight-loss programs or nutritionist services? Forget it—unless you have diabetes or kidney issues. The increased utilization of specialty drugs like GLP-1s has already been flagged as a key cost driver pushing insurance premiums higher across both private and public markets.
And what about Medicaid? States can choose whether to cover GLP-1s for obesity, and as of early 2026, only 13 states have jumped on that bandwagon. As for the rest? They’re either dragging their feet or slapping restrictions on coverage.
